Gotoh Kana, Nakajima Yoko, Tajima Go, Watanabe Yoriko, Hotta Yuji, Kataoka Tomoya, Kawade Yoshihiro, Sugiyama Naruji, Ito Tetsuya, Kimura Kazunori, Maeda Yasuhiro
Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Department of Pediatrics, Fujita Health University, Toyoake, Japan.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 1;1046:195-199. doi: 10.1016/j.jchromb.2017.02.003. Epub 2017 Feb 6.
Propionic acidemia (PA) is an inherited metabolic disease caused by low activity of propionyl coenzyme A (CoA) carboxylase (PCC), which metabolizes propionyl-CoA into methylmalonyl-CoA. Although many patients with PA have been identified by tandem mass spectrometry since the test was first included in neonatal mass screening in the 1990s, the disease severity varies. Thus, determining the specific level of PCC activity is considered to be helpful to grasp the severity of PA. We developed a new PCC assay method by the determination of methylmalonyl-CoA, which is formed by an enzyme reaction using peripheral lymphocytes, based on ultra high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). With methylmalonyl-CoA concentrations of 0.05, 0.5, and 5μmol/L, the intra-assay coefficients of variation (CVs) were 8.2%, 8.7%, and 5.1%, respectively, and the inter-assay CVs were 13.6%, 10.5%, and 5.9%, respectively. The PCC activities of 20 healthy individuals and 6 PA patients were investigated with this assay. Methylmalonyl-CoA was not detected in one PA patient with a severe form of the disease, but the remaining PA patients with mild disease showed residual activities (3.3-7.8%). These results demonstrate that determination of PCC activity with this assay would be useful to distinguish between mild and severe cases of PA to help choose an appropriate treatment plan.
丙酸血症(PA)是一种遗传性代谢疾病,由丙酰辅酶A(CoA)羧化酶(PCC)活性低下引起,该酶可将丙酰辅酶A代谢为甲基丙二酰辅酶A。自20世纪90年代串联质谱首次被纳入新生儿筛查以来,已发现许多PA患者,但疾病严重程度各不相同。因此,确定PCC活性的具体水平被认为有助于了解PA的严重程度。我们基于超高效液相色谱串联质谱(UPLC-MS/MS),通过测定外周淋巴细胞酶反应生成的甲基丙二酰辅酶A,开发了一种新的PCC检测方法。甲基丙二酰辅酶A浓度为0.05、0.5和5μmol/L时,批内变异系数(CVs)分别为8.2%、8.7%和5.1%,批间CVs分别为13.6%、10.5%和5.9%。用该检测方法对20名健康个体和6名PA患者的PCC活性进行了研究。一名重症PA患者未检测到甲基丙二酰辅酶A,但其余轻症PA患者显示有残余活性(3.3 - 7.8%)。这些结果表明,用该检测方法测定PCC活性有助于区分PA的轻症和重症病例,从而有助于选择合适的治疗方案。